Review
Copyright ©2014 Baishideng Publishing Group Inc. All rights reserved.
World J Diabetes. Oct 15, 2014; 5(5): 651-658
Published online Oct 15, 2014. doi: 10.4239/wjd.v5.i5.651
Diabetes treatment in patients with renal disease: Is the landscape clear enough?
Ioannis Ioannidis
Ioannis Ioannidis, 2nd Department of Internal Medicine, Konstantopoulio Hospital, Nea Ionia, 14233 Athens, Greece
Author contributions: Ioannidis I solely contributed to this paper.
Correspondence to: Ioannis Ioannidis, MD, PhD, Director of Diabetes Outpatient Clinic, 2nd Department of Internal Medicine, Konstantopoulio Hospital, Nea Ionia, Agias Olgas 3-5, 14233 Athens, Greece. kefion@otenet.gr
Telephone: +30-213-2057216 Fax: +30-210-2773845
Received: November 30, 2013
Revised: July 9, 2014
Accepted: July 18, 2014
Published online: October 15, 2014
Processing time: 259 Days and 20.5 Hours
Abstract

Diabetes is the most important risk factors for chronic kidney disease (CKD). The risk of CKD attributable to diabetes continues to rise worldwide. Diabetic patients with CKD need complicated treatment for their metabolic disorders as well as for related comorbidities. They have to treat, often intensively, hypertension, dyslipidaemia, bone disease, anaemia, and frequently established cardiovascular disease. The treatment of hypoglycaemia in diabetic persons with CKD must tie their individual goals of glycaemia (usually less tight glycaemic control) and knowledge on the pharmacokinetics and pharmacodynamics of drugs available to a person with kidney disease. The problem is complicated from the fact that in many efficacy studies patients with CKD are excluded so data of safety and efficacy for these patients are missing. This results in fear of use by lack of evidence. Metformin is globally accepted as the first choice in practically all therapeutic algorithms for diabetic subjects. The advantages of metformin are low risk of hypoglycaemia, modest weight loss, effectiveness and low cost. Data of UKPDS indicate that treatment based on metformin results in less total as well cardiovascular mortality. Metformin remains the drug of choice for patients with diabetes and CKD provided that their estimate Glomerular Filtration Rate (eGFR) remains above 30 mL/min per square meter. For diabetic patients with eGFR between 30-60 mL/min per square meter more frequent monitoring of renal function and dose reduction of metformin is needed. The use of sulfonylureas, glinides and insulin carry a higher risk of hypoglycemia in these patients and must be very careful. Lower doses and slower titration of the dose is needed. Is better to avoid sulfonylureas with active hepatic metabolites, which are renally excreted. Very useful drugs for this group of patients emerge dipeptidyl peptidase 4 inhibitors. These drugs do not cause hypoglycemia and most of them (linagliptin is an exception) require dose reduction in various stages of renal disease.

Keywords: Chronic kidney disease; Diabetes; Antidiabetic drugs; Metformin; Dipeptidyl peptidase 4 inhibitors; Therapeutic algorithm

Core tip: Chronic kidney disease (CKD) is very often among diabetic persons. In every day clinical practice doctors worldwide have to deal with these patients and help them to achieve their metabolic goals. Despite this, many studies of antidiabetic drugs have excluded people with CKD. So, we lack solid evidence on the effectiveness and safety of these drugs. In this review I propose therapeutic algorithms for diabetic patients in different stages of CKD and clarify some questions about the use of popular antidiabetic drugs as metformin and sulfonylureas.